Stevanato Group (STVN)
(Delayed Data from NYSE)
$20.20 USD
+0.09 (0.45%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $20.20 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value F Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Stevanato Group S.p.A. [STVN]
Reports for Purchase
Showing records 1 - 20 ( 62 total )
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Optimized Entry and Exit Levels for STVN 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Life Science Tools - ALERT: Implications of LLY Receiving FDA Approval for Zepbound
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
3Q23 Light but 27% Organic and Growing Backlog Show Clear Runway
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
GLP-1 Market Update: Potential Exceeding Past Estimates, Injection vs. Oral Outlook
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Far Horizon of Growth - Capital Markets Day
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Life Science Tech: Record Pace of 2023 FDA Approvals, Defies Investor Skepticism, Promises 2024 Normalcy
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
2Q23 Beats Estimates with 20% Organic; Maintains FY23; GLP-1 Early Days
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
1Q23 - BioProcess and GLP-1 Tailwinds Building; Raising PT to $35
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
Interphex - Activity, Tone and Technology Present Compelling Future for Bioprocessing
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Stevanato Group S.p.A.
Industry: Medical - Drugs
2023 Life Sciences & MedTech Investor Forum: Key Takeaways
Provider: KeyBanc Capital Markets
Analyst: Research Department